Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.
Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') or or Authorisation for Early Access (AAP). A Prospective Cohort.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Youri Yordanov, Dr
- Phone Number: 01 71 97 08 69
- Email: youri.yordanov@aphp.fr
Study Contact Backup
- Name: Guillaume Martin-Blondel, Pr
- Phone Number: 05 61 77 96 99
- Email: martin-blondel.g@chu-toulouse.fr
Study Locations
-
-
-
Agen, France
- CH Agen-Nérac
-
Angers, France
- CHU d'Angers
-
Ars-Laquenexy, France
- CHR Metz-Thionville
-
Bobigny, France
- Hopital Avicenne
-
Bordeaux, France, 33076
- CHU de Bordeaux
-
Clermont-Ferrand, France
- Chu Gabriel Montpied
-
Corbeil-Essonnes, France, 91106
- Centre Hospitalier Sud Francilien - Hématologie
-
Corbeil-Essonnes, France, 91106
- Centre Hospitalier Sud Francilien - Néphrologie
-
Dijon, France
- CHU de Dijon
-
Fort-de-France, France, 97261
- CHU de Martinique
-
Le Kremlin-Bicêtre, France, 94275
- Hôpital Bicêtre - Médecine interne
-
Le Kremlin-Bicêtre, France, 94275
- Hôpital Bicêtre - SMIT
-
Limoges, France
- CHU de Limoges
-
Lyon, France
- Hospices Civils de Lyon (HCL)
-
Montpellier, France
- CHU de Montpellier
-
Nancy, France, 54511
- CHRU de Nancy
-
Nantes, France
- CHU de Nantes
-
Nîmes, France
- CHU de Nîmes
-
Paris, France
- Hôpital Pitié-Salpêtrière
-
Paris, France, 75012
- Hopital Saint Antoine
-
Paris, France, 75020
- Hôpital Tenon
-
Paris, France
- Hôpital Saint-Louis
-
Paris, France, 75018
- Hopital Bichat Claude-Bernard
-
Paris, France, 75010
- Hôpital Lariboisière - SMIT
-
Paris, France
- Hôpital Bichat Claude-Bernard - SAU
-
Paris, France
- Hôpital Lariboisière - SAU SMUR
-
Paris, France
- Hôpital Saint Antoine - SAU
-
Paris, France
- Hôpital Universitaire Necker Enfants Malades
-
Paris, France
- Hôpitaux Cochin - Port Royal
-
Poissy, France
- CHI Poissy St Germain en Laye
-
Poitiers, France
- CHU De Poitiers
-
Rennes, France
- CHU de Rennes
-
Tarbes, France
- CH de Tarbes
-
Toulouse, France
- CHU de Toulouse
-
Toulouse, France
- CHU de Toulouse - IUCT - Oncopole
-
Tourcoing, France
- CH de Tourcoing
-
Tours, France
- CHRU de Tours - Hopital Bretonneau
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults with the criteria for COVID-19 treatment within the French compassionate program (ATU/AAP)
- Adults covered by the French social health coverage
- Adults who signed the informed consent form
Exclusion Criteria:
- Exclusion criteria described in the French compassionate program (ATU/AAP)
- Patient participating in another biomedical research with an exclusion period ongoing at inclusion
- Vulnerable patient (adults legally protected: under judicial protection, guardianship, or supervision, persons deprived of their liberty)
- Pregnant or breastfeeding woman
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients treated with casirivimab/imdevimab according to the ATU protocol
|
|
|
Patients treated with bamlanivimab/etesevimab according to the ATU protocol
|
|
|
Patients treated with Xevudy according to the authorisation for early access (AAP) protocol
|
|
|
Patients treated with Paxlovid according to the authorisation for early access (AAP) protocol
|
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of patients hospitalized (if the patient was outpatient) or whose hospitalization was extended for complications from COVID-19 within 1 month of symtoms' onset.
Time Frame: Month 1
|
Month 1
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of patients hospitalized whatever the reason
Time Frame: Month 1 and 3
|
Month 1 and 3
|
|
|
Percentage of patients with an WHO score >= 5
Time Frame: Month 1
|
Month 1
|
|
|
Percentage of patients staying in an Intensive Care Unit in the month following symptoms' onset
Time Frame: Month 1
|
Month 1
|
|
|
Percentage of patients who died from COVID-19 complications and any other reason
Time Frame: Month 1
|
Month 1
|
|
|
Percentage of patients presenting a adverse event and percentage of treatment discontinuation caused by those adverse events
Time Frame: Month 1
|
Month 1
|
|
|
Time between first symptoms and treatment and the reasons for this delay
Time Frame: Day 0
|
Day 0
|
|
|
Virological response
Time Frame: Day 7 for ambulatory patients, Day 3, 5 and 7 for hospitalized patients
|
Percentage of virological response defined by CT>=31 or negative PCR test +
|
Day 7 for ambulatory patients, Day 3, 5 and 7 for hospitalized patients
|
|
Virological criteria linked to the emergence of resistance
Time Frame: from inclusion until a negative PCR test or Ct ≥31 is obtained
|
Percentage of patients included developing resistance variants, genotypic and phenotypic characterization of resistance variants
|
from inclusion until a negative PCR test or Ct ≥31 is obtained
|
|
Percentage of patients with positive anti-N and anti-S serology
Time Frame: Day 0 and Month 3
|
Day 0 and Month 3
|
|
|
anti-S antibody level
Time Frame: Day 0 and Month 3
|
Day 0 and Month 3
|
|
|
Flow cytometry cartography of myeloid response
Time Frame: Day 0, 7 and Month 1
|
Flow cytometry cartography of myeloid (functional subtypes of monocytes and dendritic cells) response
|
Day 0, 7 and Month 1
|
|
Flow cytometry cartography of T-lymphocyte response
Time Frame: Day 0, 7 and Month 1
|
Flow cytometry cartography of T-lymphocyte (conventional T-lymphocytes by identifying naïve, memory and effector Th1, Th2, Tfh and Th17 T-lymphocytes, NK and gamma-delta T-lymphocytes, regulatory T-lymphocytes; surface and intracellular markers) response
|
Day 0, 7 and Month 1
|
|
Flow cytometry cartography of B-lymphocyte response
Time Frame: Day 0, 7 and Month 1
|
Flow cytometry cartography of B-lymphocyte (transitional, naïve, memory T-lymphocyte with or without isotypic switching, plasmablasts) response
|
Day 0, 7 and Month 1
|
|
Dosing of a wide range of cytokines and chemokines (IFNalpha, IFNgamma, IL-6, IL-1, IL-8, IL-15, IL-18, IL1-RA, IL-7, IL-10, CXCL10, CXCL13, CCL2 and CCL3) using the Meso Scale Discovery approach
Time Frame: Day 0, 7 and Month 1
|
Day 0, 7 and Month 1
|
|
|
Clinical and biological predictors (clinical parameters, treatment received, virological criteria (cycle threshold (CT), variants) of the onset of complications from COVID19, hospitalization, death
Time Frame: from inclusion until the end of the follow-up (Month 1 or Month 3)
|
Identication of clinical and biological predictors of the onset of complications from COVID19, hospitalization, death by a logistic model or survival model (RMST): the response variable is the occurrence of a complication, hospitalization, death or the average survival at 1 month on these different criteria; the covariates are the parameters at inclusion, the treatment received, the virological criteria (CT, variants) which can be considered as a time-dependent covariate
|
from inclusion until the end of the follow-up (Month 1 or Month 3)
|
|
Clinical and biological predictive factors (clinical parameters, treatment received, virological criteria (cycle threshold (CT), variants)) linked to the neutralizing serological response: non-response, duration of the response
Time Frame: from inclusion until the end of the follow-up (Month 1 or Month 3)
|
Identification of clinical and biological predictive factors (clinical parameters, treatment received, virological criteria (cycle threshold (CT), variants)) linked to the neutralizing serological response: non-response, duration of the response by a logistic model or mixed model for repeated measures
|
from inclusion until the end of the follow-up (Month 1 or Month 3)
|
|
Clinical and biological predictors (clinical parameters, treatment received, virological criteria) of viral response (viral genotypes, emergence of resistant strains)
Time Frame: from inclusion until the end of the follow-up (Month 1 or Month 3)
|
Identification of clinical and biological predictive factors related to the virological response (viral genotypes, emergence of resistant strains) by a logistic model: the response variable is RT-PCR negativation at D7 (or CT≥31), the covariates are the parameters at inclusion, the treatment received, the virological criteria at baseline
|
from inclusion until the end of the follow-up (Month 1 or Month 3)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Youri Yordanov, Dr, Saint Antoine Hospital
Publications and helpful links
General Publications
- Bruel T, Vrignaud LL, Porrot F, Staropoli I, Planas D, Guivel-Benhassine F, Puech J, Prot M, Munier S, Henry-Bolland W, Soulie C, Zafilaza K, Lusivika-Nzinga C, Meledge ML, Dorival C, Molino D, Pere H, Yordanov Y, Simon-Loriere E, Veyer D, Carrat F, Schwartz O, Marcelin AG, Martin-Blondel G; ANRS 0003S CoCoPrev Study Group. Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients. medRxiv [Preprint]. 2023 May 30:2023.05.25.23290512. doi: 10.1101/2023.05.25.23290512.
- Bruel T, Vrignaud LL, Porrot F, Staropoli I, Planas D, Guivel-Benhassine F, Puech J, Prot M, Munier S, Bolland WH, Soulie C, Zafilaza K, Lusivika-Nzinga C, Meledge ML, Dorival C, Molino D, Pere H, Yordanov Y, Simon-Loriere E, Veyer D, Carrat F, Schwartz O, Marcelin AG, Martin-Blondel G; ANRS 0003S CoCoPrev Study Group. Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients. Med. 2023 Oct 13;4(10):664-667. doi: 10.1016/j.medj.2023.07.007.
- Martin-Blondel G, Marcelin AG, Soulie C, Kaisaridi S, Lusivika-Nzinga C, Zafilaza K, Dorival C, Nailler L, Boston A, Ronchetti AM, Melenotte C, Cabie A, Choquet C, Trinh-Duc A, Lacombe K, Gaube G, Coustilleres F, Pourcher V, Martellosio JP, Peiffer-Smadja N, Chauveau M, Housset P, Piroth L, Devaux M, Pialoux G, Martin A, Dubee V, Frey J, Le Bot A, Cazanave C, Petua P, Liblau R, Carrat F, Yordanov Y. Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir. Clin Microbiol Infect. 2023 Apr;29(4):543.e5-543.e9. doi: 10.1016/j.cmi.2022.12.016. Epub 2022 Dec 28.
- Martin-Blondel G, Marcelin AG, Soulie C, Kaisaridi S, Lusivika-Nzinga C, Dorival C, Nailler L, Boston A, Melenotte C, Gaube G, Choquet C, Liblau R, Carrat F, Yordanov Y; COCOPREV Study Group. Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study). J Infect. 2022 Jun;84(6):e101-e104. doi: 10.1016/j.jinf.2022.04.010. Epub 2022 Apr 7. No abstract available.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ANRS0003S COCOPREV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.